Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

Idris Bahce*, Marc C. Huisman, Eline E. Verwer, Rogier Ooijevaar, Firdaouss Boutkourt, Danielle J. Vugts, Guus A.M.S. van Dongen, Ronald Boellaard, Egbert F. Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background: The aim of this pilot study was to evaluate whether the uptake of 89Zr-bevacizumab in non-small cell lung cancer (NSCLC) tumors could be visualized and quantified. The correlation between tumor 89Zr-bevacizumab uptake and tumor response to antitumor therapy with a bevacizumab-based regimen was explored. Methods: Seven NSCLC patients underwent static PET scans at days 4 and 7 after injection of 36.4 ± 0.9 MBq (mean ± SD) 89Zr-bevacizumab, prior to commencing carboplatin-paclitaxel-bevacizumab chemotherapy (CPB). Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak). Results: Zr-bevacizumab uptake (SUVpeak) was approximately four times higher in tumor tissues (primary tumor and metastases) than in non-tumor tissues (healthy muscle, lung, and fat) on days 4 and 7. A positive trend but no significant correlation could be found between SUVpeak and OS or PFS. Conclusions: This pilot study shows that 89Zr-bevacizumab PET imaging in NSCLC is feasible. Further investigation to validate this technique as a predictive biomarker for selecting patients for bevacizumab treatment is warranted.

Original languageEnglish
Article number35
Pages (from-to)1-7
Number of pages7
JournalEJNMMI Research
Issue number1
Publication statusPublished - 1 Dec 2014

Cite this